RNTX’s LTI-03 advances global Phase II for IPF
LTI-03, an inhaled peptide for idiopathic pulmonary fibrosis (IPF), is enrolling globally in Phase II; interim data are expected this year and full results late 2027.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.